Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.44 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.44 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23514532 | 1.00 | DPP8 (0.49) | DPP8CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL23514441 | 0.94 | DPP8 (0.46) | DPP8CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL23514549 | 0.88 | PHGDH (0.46) | DPP8CHRM1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL23514438 | 0.88 | PHGDH (0.46) | DPP8CHRM1L3MBTL3L3MBTL1MEN1 | |
| SCHEMBL23514436 | 0.87 | PHGDH (0.38) | DPP8CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL23514538 | 0.87 | PHGDH (0.38) | DPP8CHRM1L3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL23499910 | 0.86 | PHGDH (0.45) | DPP8CHRM1L3MBTL3L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL23499909 | 0.86 | DPP8 (0.39) | DPP8CHRM1 | |
| SCHEMBL15853678 | 0.83 | DPP7 (0.41) | DPP8 | |
| SCHEMBL23514432 | 0.82 | PHGDH (0.42) | CHRM1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021119475-A1 | CYSTINE DIAMIDE ANALOGS FOR CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | CTH, CBS, SLC7A11 | DPP8 621/4885CHRM1 3121/4885L3MBTL3 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.